论文部分内容阅读
肝脏是恶性肿瘤最常见的血行转移器官之一,其中多数肝转移癌的原发肿瘤来自消化系统,尤以结、直肠多见。目前肝转移癌首选的治疗仍然是手术切除[1-2],肝转移灶可根治性切除患者的中位生存期为35个月,5年生存率达30%～50%[3],但是由于病灶多发、散在分布、患者不能耐受等多种原因,仅有10%～20%的患者能获得手术切除[4]。对于各种肝转移癌不宜手术者,如不愿意接受手术、多发结节、肿瘤位置深在紧贴大血管等各种原因不能进行手术切除者,可采取多种微创治疗。微
Liver is one of the most common hematological metastases of malignant tumors, of which most of the primary tumors of liver metastases come from the digestive system, especially in the nodes and rectum. Currently, the first choice of treatment of liver metastases is still surgical resection [1-2]. The median survival of patients with hepatic metastases resection is 35 months and the 5-year survival rate is 30% -50% [3] Due to multiple lesions, scattered distribution, patients can not tolerate a variety of reasons, only 10% to 20% of patients get surgical resection [4]. For a variety of liver metastases should not be surgery, such as reluctant to accept surgery, multiple nodules, the tumor deep in close proximity to large blood vessels and other reasons can not be removed, can take a variety of minimally invasive treatment. micro-